Isfahan University of Medical Sciences Journal of Isfahan Medical School 1027-7595 29 173 2012 02 20 The Effect of Methotrexate 1% Topical Gel on Psoriasis The Effect of Methotrexate 1% Topical Gel on Psoriasis 3087 3092 13715 FA Gita Faghihi Associate Professor, Skin Diseases and Leishmaniasis Research Center And Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0002-9106-3052 Taghi Ghafghazi Professor, Department of Pharmacology and Toxicology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan Iran Mohammad Ali Nilforoushzadeh Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Journal Article 2012 03 18 Background: Psoriasis is one of the most important chronic inflammatory skin diseases, which affects about 3% of people all over the world. However, there is still no unique approach available for treatment of this disease, despite several studies which were performed regarding efficacy and safety of various drugs including methotrexate.Methods: This randomized double-blind study recruited 65 patients with documented psoriasis. Patients were randomly divided into two groups to receive a daily dose of topical gel of methotrexate 1% (group A) or placebo gel (group B) for two months. Patients were followed up to four months.Findings: There were 65 patients, 48 male (75.3%) and 17 female (24.7%), with the mean age of 31 ± 15.7 years and the mean disease duration of 5.5 ± 3.3 years. No significant difference was detected between the two groups of patients according to the response scale after four months. Conclusion: The present study showed that the topical gel methotrexate 1%, when prepared on a base of glycerin, is not effective in improvement of the psoriasis lesions and can not be considered as a first line treatment option in this disease. Background: Psoriasis is one of the most important chronic inflammatory skin diseases, which affects about 3% of people all over the world. However, there is still no unique approach available for treatment of this disease, despite several studies which were performed regarding efficacy and safety of various drugs including methotrexate.Methods: This randomized double-blind study recruited 65 patients with documented psoriasis. Patients were randomly divided into two groups to receive a daily dose of topical gel of methotrexate 1% (group A) or placebo gel (group B) for two months. Patients were followed up to four months.Findings: There were 65 patients, 48 male (75.3%) and 17 female (24.7%), with the mean age of 31 ± 15.7 years and the mean disease duration of 5.5 ± 3.3 years. No significant difference was detected between the two groups of patients according to the response scale after four months. Conclusion: The present study showed that the topical gel methotrexate 1%, when prepared on a base of glycerin, is not effective in improvement of the psoriasis lesions and can not be considered as a first line treatment option in this disease. https://jims.mui.ac.ir/article_13715_c5a264a82289018331673285e24d9dd8.pdf